文献速递生殖医学

高龄女性IVF/ICSI周期中单用hCG、单用GnRH激动剂或联合触发排卵的随机对照试验

Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles.
PubMed 文献 · Hum Reprod · 2022-01-01

这项开放标签随机对照试验纳入510例≥35岁、低OHSS风险、采用非垂体降调节方案的IVF/ICSI女性,比较单用hCG 6000 IU、单用曲普瑞林0.2 mg及双触发(曲普瑞林0.2 mg+ hCG 2000 IU)对获卵数的影响。双触发组优质胚胎数和可移植胚胎数显著高于两个单触发组,但获卵数与单触发组无显著差异;冻胚移植后双触发组活产率和持续妊娠率显著高于GnRHa单触发组,但与hCG组无显著差异。

要点

  • 双触发组获卵率87.9%,高于hCG组84.1%(P=0.031)和GnRHa组83.6%(P=0.014)。
  • 双触发组优质胚胎数1.74±1.90,高于hCG组1.19±1.45(P=0.016)和GnRHa组1.20±1.67(P=0.003)。
  • 冻胚移植后双触发组活产率32.6%,高于GnRHa组14.1%(P=0.007),与hCG组27.9%无显著差异(P=0.537)。

核心结论

  • 在≥35岁、低OHSS风险女性中,双触发或单用hCG触发可能优于单用GnRHa触发。

研究设计与样本

  • 开放标签随机对照试验,510例参与者,于单一生殖医学中心2019年1月至2021年12月开展。
  • 计划每组招募170例、共510例,样本量基于回顾性分析本院既往临床数据计算。
  • 纳入≥35岁、接受IVF/ICSI治疗、采用非垂体降调节方案且OHSS低风险女性。
  • 触发日随机分为三组:单用hCG组(hCG 6000 IU)、单用GnRHa组(曲普瑞林0.2 mg)和双触发组(曲普瑞林0.2 mg + hCG 2000 IU)。
  • 主要结局为获卵数;次要结局包括成熟卵母细胞数及率、双原核(2PN)胚胎数及率、优质胚胎数及率,以及OHSS率、临床妊娠率、流产率和活产率。

主要发现

  • 三组基线人口学特征无显著差异。
  • 双触发组获卵率87.9%,高于hCG组84.1%(P=0.031)和GnRHa组83.6%(P=0.014)。
  • 双触发组获卵数4.08±2.79,与hCG组3.60±2.71(P=0.080)和GnRHa组3.81±3.38(P=0.101)无显著差异。
  • 双触发组优质胚胎数1.74±1.90,高于hCG组1.19±1.45(P=0.016)和GnRHa组1.20±1.67(P=0.003);可移植胚胎数2.19±2.11,高于hCG组1.56±1.66(P=0.008)和GnRHa组1.45±1.75(P=0.001)。
  • 冻胚移植后双触发组活产率32.6%,高于GnRHa组14.1%(P=0.007),与hCG组27.9%无显著差异(P=0.537);持续妊娠率34.8%,高于GnRHa组17.6%(P=0.013),与hCG组27.9%无显著差异(P=0.358)。

关键数值与推荐

  • 双触发组获卵率87.9% vs hCG组84.1%(P=0.031)。
  • 双触发组获卵率87.9% vs GnRHa组83.6%(P=0.014)。
  • 双触发组优质胚胎数1.74±1.90 vs hCG组1.19±1.45(P=0.016)。
  • 双触发组优质胚胎数1.74±1.90 vs GnRHa组1.20±1.67(P=0.003)。
  • 冻胚移植后双触发组活产率32.6% vs GnRHa组14.1%(P=0.007);双触发组持续妊娠率34.8% vs GnRHa组17.6%(P=0.013)。

临床怎么用

  • 作者认为,在低OHSS风险的≥35岁女性中,双触发或单用hCG触发可能比单用GnRHa触发是更好的选择。

局限性

  • 高龄女性人群异质性较大,与卵巢低反应或卵巢储备功能减退患者存在重叠,因此不能完全排除选择偏倚或混杂因素。
  • 本研究非双盲试验,GnRHa组和双触发组患者可能受到安慰剂效应影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is a dual ovulation trigger with a combination of GnRH agonist (GnRHa) and hCG superior to single hCG and/or single GnRHa trigger in improving treatment outcomes in advanced-age women (aged ≥ 35 years) undergoing IVF/ICSI treatment? SUMMARY ANSWER: Co-administration of GnRHa and hCG as a dual trigger increases the number of good-quality embryos but it is not associated with a higher number of oocytes retrieved, compared with single hCG or GnRHa trigger. WHAT IS KNOWN ALREADY: Many studies have demonstrated that a dual trigger has positive impact on oocyte maturation, retrieval rate and pregnancy rate without increasing the risk of ovarian hyperstimulation syndrome (OHSS) in some groups of IVF patients, when compared with single hCG trigger. Few studies have however been conducted to compare a dual trigger with a single GnRHa trigger, and insufficient evidence exists to support which trigger can achieve the best outcomes in IVF patients aged ≥35 years. STUDY DESIGN, SIZE, DURATION: This was an open-label randomized controlled trial of 510 participants conducted at single reproductive medical center from January 2019 to December 2021. After a sample size calculation performed by retrospectively analyzing our previous clinical data, we planned to recruit 170 patients in each group and 510 patients in total for the study. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial. On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups. The primary outcome parameter was the number of retrieved oocytes. The secondary outcome parameters included, among others, the number and rates of mature oocytes, two pronuclei (2PN) embryos and good-quality embryos, as the rates of OHSS, clinical pregnancy, miscarriage and live birth. MAIN RESULTS AND THE ROLE OF CHANCE: There were no significant differences in the baseline demographic characteristics among the three groups. The dual trigger was associated with a higher retrieval rate (87.9% vs 84.1% in the hCG group, P = 0.031; 87.9% vs 83.6% in the GnRHa group, P = 0.014). However, the number of retrieved oocytes in the dual trigger group was comparable with those in the hCG group (4.08 ± 2.79 vs 3.60 ± 2.71, P = 0.080) and the GnRHa group (4.08 ± 2.79 vs 3.81 ± 3.38, P = 0.101); comparable data between the groups were also found when analyzing the number of 2PN embryos and the 2PN rate. In the dual trigger group, the numbers of good-quality embryos and viable embryos were both significantly higher than in the hCG group (1.74 ± 1.90 vs 1.19 ± 1.45, P = 0.016 and 2.19 ± 2.11 vs 1.56 ± 1.66, P = 0.008, respectively) and the GnRHa group (1.74 ± 1.90 vs 1.20 ± 1.67, P = 0.003 and 2.19 ± 2.11 vs 1.45 ± 1.75, P = 0.001, respectively). Pregnancy outcomes after fresh embryo transfer (ET) were comparable between the groups. The live birth rate and ongoing pregnancy rate after frozen ET in the dual trigger group were significantly higher than those in the GnRHa group (32.6% vs 14.1%, P = 0.007 and 34.8% vs 17.6%, P = 0.013, respectively), but not superior to those in the hCG group (32.6% vs 27.9%, P = 0.537 and 34.8% vs 27.9%, P = 0.358, respectively). LIMITATIONS, REASONS FOR CAUTION: Women of advanced age are quite a heterogeneous population and overlap with poor ovarian responders or patients with diminished ovarian reserve. We therefore could not entirely exclude selection biases or confounding factors. This study was also not a double-blinded trial; the patients in the GnRHa and dual trigger groups could have been affected by the placebo effect. WIDER IMPLICATIONS OF THE FINDINGS: The results of this study suggest that in advanced-age women with low risk of OHSS, a dual trigger or even a single hCG trigger may be a better choice than a single GnRHa trigger. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the Shanghai Municipal Health Commission of Science and Research Fund (20184Y0289). The authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: This trial was registered in the Chinese Clinical Trial Registry (ChiCTR-1800016285). TRIAL REGISTRATION DATE: 24 May 2018. DATE OF FIRST PATIENT’S ENROLMENT: 2 January 2019.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Zhou C, Yang X, Wang Y, et al. Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles. Hum Reprod. 2022. PMID: 35595223. doi:10.1093/humrep/deac114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。